Inventory Disclosure [Abstract] Work in-process inventory Inventory, Work in Process, Gross Fair Value Disclosures [Abstract] Fair Value Measurements Fair Value Disclosures [Text Block] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Earnings Per Share [Abstract] Schedule of earnings per share reconciliation Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Schedule of antidilutive securities excluded from computation of earnings per share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Related Party Transactions [Abstract] Related Party Transactions Related Party Transactions Disclosure [Text Block] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Stock Options Stock Options [Member] Stock-Settled Stock Appreciation Rights Stock Appreciation Rights (SARs) [Member] Restricted Stock Units Restricted Stock Units (RSUs) [Member] Warrants Warrant [Member] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Weighted average number Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Weighted average exercise price Antidilutive Securities Excluded from Computation of Earnings Per Share, Weighted Average Exercise Price Antidilutive Securities Excluded from Computation of Earnings Per Share, Weighted Average Exercise Price Organization, Consolidation and Presentation of Financial Statements [Abstract] Interim Condensed Consolidated Financial Statements Basis of Presentation and Significant Accounting Policies [Text Block] Research and Development [Abstract] Procurement Contract [Table] Procurement Contract [Table] Procurement Contract [Table] Procurement Contract [Axis] Procurement Contract [Axis] Procurement Contract [Axis] Procurement Contract [Domain] Procurement Contract [Domain] Procurement Contract [Domain] BARDA Contract Barda Contract [Member] Barda Contract [Member] Procurement Contract [Line Items] Procurement Contract [Line Items] Procurement Contract [Line Items] Number of courses to be delivered Number of Courses To Be Delivered Number of ST-246 courses to be delivered to the U.S. Strategic National Stockpile Government contract, duration Base Government Contract, Duration Base Government Contract, Duration Value of contract Government Contract, Value of Award Value of five-year base contract award Option to purchase additional courses Government Contract, Maximum Number of Additional Courses Available to Purchase Government contract, maximum number of additional courses available to purchase by the U.S. government, subsequently withdrawn from final contract. Number of courses under modified contract Government Contract, Number of Courses Purchased Under Modified Contract Government contract, number of courses to be purchased under modified contract. Number of courses manufactured using federal funds Government Contract, Number of Courses Manufactured Using Federal Funds Government contract, number of courses to be delivered that were manufactured using federal funds under prior development contracts. Proceeds from advance payments under the BARDA contract Proceeds from Advance Payments, Government Contracts Proceeds from Advance Payments, Government Contracts Deferred costs Deferred Costs, Noncurrent Deferred revenue, additions from BARDA contract Deferred Revenue, Additions Milestone payment Milestone payment Proceeds from milestone payment, Government contracts Number of active grants Government Contract, Number of Active Grants Government Contract, Number of Active Grants Expected research and development expense Expected Potential Future Aggregate Research and Development Expenses Expected potential future aggregate research and development funding for specific projects which includes options that may or may not be exercised at the U.S. government's discretion. Accounts receivable Contract Receivable Statement of Financial Position [Abstract] Statement [Table] Statement [Table] Scenario [Axis] Scenario [Axis] Scenario, Unspecified [Domain] Scenario, Unspecified [Domain] Statement [Line Items] Statement [Line Items] ASSETS Assets [Abstract] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Accounts receivable Accounts Receivable, Net, Current Inventory Inventory, Net Prepaid expenses Prepaid Expense, Current Deferred tax assets Deferred Tax Assets, Net of Valuation Allowance, Current Total current assets Assets, Current Property, plant and equipment, net Property, Plant and Equipment, Net Goodwill Goodwill Other assets Other Assets, Noncurrent Deferred tax assets, net Deferred Tax Assets, Net of Valuation Allowance, Noncurrent Total assets Assets LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities and Equity [Abstract] Accounts payable Accounts Payable, Current Accrued expenses and other current liabilities Accrued Liabilities, Current Total current liabilities Liabilities, Current Deferred revenue Deferred Revenue, Noncurrent Common stock warrants Common Stock Warrants, Noncurrent, Fair Value Disclosure This item represents non-current portion of a security that gives the holder the right to purchase shares of common stock in accordance with the terms of the instrument, usually upon payment of a specified amount. Other liabilities Other Liabilities Total liabilities Liabilities Stockholders' equity Stockholders' Equity Attributable to Parent [Abstract] Common stock ($.0001 par value, 100,000,000 shares authorized, 51,638,352 and 51,637,352 issued and outstanding at June 30, 2012, and December 31, 2011, respectively Common Stock, Value, Issued Additional paid-in capital Additional Paid in Capital, Common Stock Accumulated deficit Retained Earnings (Accumulated Deficit) Total stockholders' equity Stockholders' Equity Attributable to Parent Total liabilities and stockholders' equity Liabilities and Equity Period in which current funds are sufficient to cover operations Minimum Period in Which Current Funds is Sufficient to Cover Future Operations Minimum period in which current funds is sufficient to cover future operations. Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Stock Compensation Plans Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Payables and Accruals [Abstract] Accrued Expenses Accrued expenses and other current liabilities [Text Block] The entire disclosure for accrued liabilities and other current liabilities at the end of the reporting period. Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Award Type [Axis] Award Type [Axis] Award Type [Domain] Award Type [Domain] Range [Axis] Range [Axis] Range [Domain] Range [Domain] Minimum Minimum [Member] Maximum Maximum [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Number of shares authorized Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Stock-based compensation expense Allocated Share-based Compensation Expense Number of shares granted Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Weighted average grant-date fair value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Award vesting period Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Award expiration period Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period Number of shares potentially issuable Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares that Could Be Issued Share-based compensation arrangement by share-based payment award, maximum number of shares that could be issued Unrecognized stock-based compensation cost Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Share-based Awards Other than Options Expected volatility Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Expected life from grant date Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Expected dividend yield Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Risk-free interest rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Inventory Inventory Disclosure [Text Block] Income Statement [Abstract] Revenues Revenues [Abstract] Research and development Research and Development Revenue Revenue earned during the period arising from services provided under the terms of a contract, not elsewhere specified in the taxonomy. May include government contracts and any other contract related to a particular project or product. Operating expenses Operating Expenses [Abstract] Selling, general and administrative Selling, General and Administrative Expense Research and development Research and Development Expense Patent preparation fees Patent Preparation Fees The aggregate costs incurred for fees associated with the protection and expansion of patents and related intellectual property. Total operating expenses Operating Expenses Operating loss Operating Income (Loss) Decrease (increase) in fair value of common stock warrants Change In Fair Value Of Common Stock Warrants The aggregate adjustment to the fair market value of liability classified warrants to purchase common stock. Other income, net Nonoperating Income (Expense) Loss before income taxes Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest Benefit from income taxes Income Tax Expense (Benefit) Net income (loss) Net Income (Loss) Attributable to Parent Basic earnings (loss) per share Earnings Per Share, Basic Diluted earnings (loss) per share Earnings Per Share, Diluted Weighted average shares outstanding: basic Weighted Average Number of Shares Outstanding, Basic Weighted average shares outstanding: diluted Weighted Average Number of Shares Outstanding, Diluted Per Share Data Earnings Per Share [Text Block] Vacation Accrued Vacation, Current Bonus Accrued Bonuses, Current Professional fees Accrued Professional Fees, Current Loss contingency Loss Contingency, Accrual Carrying Value, Current Other Other Accrued Liabilities, Current Total Statement of Cash Flows [Abstract] Cash and Cash Equivalents, Period Increase (Decrease) [Abstract] Cash and Cash Equivalents, Period Increase (Decrease) [Abstract] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Net income (loss) Adjustments to reconcile net income (loss) to net cash used in operating activities Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Depreciation and other amortization Depreciation, Depletion and Amortization Increase (decrease) in fair value of warrants Increase In Fair Value Of Warrants Noncash expense, not otherwise specified in the taxonomy, charged against earnings in the period to adjust the fair market value of liability classified warrants to purchase common stock. Stock based compensation Share-based Compensation Changes in assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Accounts receivable Increase (Decrease) in Accounts Receivable Inventory Increase (Decrease) in Inventories Deferred costs Increase (Decrease) in Deferred Charges Accrued interest on short-term investments Increase (Decrease) in Accrued Interest Receivable, Net Prepaid expenses Increase (Decrease) in Prepaid Expense Other assets Increase (Decrease) in Other Operating Assets Deferred income taxes, net Deferred Income Tax Expense (Benefit) Accounts payable, accrued expenses and other current liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Deferred revenue Increase (Decrease) in Deferred Revenue Other liabilities Increase (Decrease) in Other Operating Liabilities Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Capital expenditures Payments to Acquire Property, Plant, and Equipment Collateral for surety bond Payment of collateral for commercial surety bond The net cash outflow of funds paid as collateral for a commercial surety bond that are classified as investing activities. Proceeds from maturity of short term investments Proceeds from Sale and Maturity of Available-for-sale Securities Purchases of short term investments Payments to Acquire Short-term Investments Net cash (used in) provided by investing activities Net Cash Provided by (Used in) Investing Activities Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Net proceeds from exercise of warrants and options Proceeds From Issuance Of Warrants and Options The cash inflow associated with both the amount received from holders exercising their stock options and issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt). This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately. Repurchase of common stock Payments for Repurchase of Common Stock Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Net decrease in cash and cash equivalents Cash and Cash Equivalents, Period Increase (Decrease) Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Supplemental disclosure of non-cash financing activities: Supplemental Cash Flow Information [Abstract] Reclass of common stock warrant liability to additional paid-in capital upon warrant exercise Reclass of Common Stock Warrant Liability To Additional Paid In Capital Upon Exercise Value of reclass of common stock warrant liability to additional paid-in capital upon exercise in noncash financing activities. Procurement Contract and Research Agreements Procurement Contract and Research Agreements [Text Block] The entire disclosure for procurement contracts and research agreements including grants or contracts from various agencies of the U.S. government to support the reporting entity's research and development activities. Income Tax Disclosure [Abstract] Income Tax Income Tax Disclosure [Text Block] Schedule of Related Party Transactions, by Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Related Party [Axis] Related Party [Axis] Related Party [Domain] Related Party [Domain] Affiliated Entity Affiliated Entity [Member] Member of Board of Directors Management [Member] Extended expiration period Extended Expiration Period [Member] Extended Expiration Period [Member] Related Party Transaction [Line Items] Related Party Transaction [Line Items] Lease property, price per month Lease Property Price Per Month Lease Property Price Per Month Lease agreement, cancellation period Lease Agreement, Cancellation Period Lease agreement cancellation period Number of shares called by warrants Class of Warrant or Right, Number of Securities Called by Warrants or Rights Plan modification, incremental compensation cost Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Incremental Compensation Cost Legal fees Legal Fees Accounts payable to related party Accounts Payable, Related Parties Loss Contingencies [Table] Loss Contingencies [Table] Litigation Case [Axis] Litigation Case [Axis] Litigation Case Type [Domain] Litigation Case Type [Domain] License Agreement litigation License Agreement Litigation [Member] License Agreement Litigation [Member] Litigation Status [Axis] Litigation Status [Axis] Litigation Status [Domain] Litigation Status [Domain] Pending litigation Pending Litigation [Member] Loss Contingency Nature [Axis] Loss Contingency Nature [Axis] Loss Contingency, Nature [Domain] Loss Contingency, Nature [Domain] Surety bond Surety Bond [Member] Balance Sheet Location [Axis] Balance Sheet Location [Axis] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Accrued liabilities Accrued Liabilities [Member] Other assets Other Assets [Member] Loss Contingencies [Line Items] Loss Contingencies [Line Items] Equitable payment stream following first commercial sale, duration Duration of Equitable Payment Stream Following First Commercial Sale The Delaware Court of Chancery awarded to PharmAthene an equitable payment stream or equitable lien consisting of fify percent of the net profits that the Company achieves from sales of ST-246 after the Company secures $40 million in net profits, for ten years following the first commercial sale. Percentage of net profits from sales after net profit threshold Percentage of Net Profits from Sales After Net Profit Milestone Resulting From Award Damages The Delaware Court of Chancery awarded to PharmAthene an equitable payment stream or equitable lien consisting of fify percent of the net profits that the Company achieves from sales of ST-246 after the Company secures $40 million in net profits, for ten years following the first commercial sale. Net profit threshold Net Profit Milestone The Delaware Court of Chancery awarded to PharmAthene an equitable payment stream or equitable lien consisting of fify percent of the net profits that the Company achieves from sales of ST-246 after the Company secures $40 million in net profits, for ten years following the first commercial sale Accrued liabilities, current Loss Contingency Accrual, at Carrying Value Plaintiff attorneys' fee and expenses Amount Plaintiff May Recover The Delaware Court of Chancery awarded PharmAthene one-third of its reasonable attorneys' fees and expert witness expenses. Payment to post collateral for surety bond Payment to Post Collateral for Surety Bond Payment to post collateral for surety bond. Percentage of litigation costs awarded Litigation Costs Awarded, Percentage The Delaware Court of Chancery awarded PharmAthene one-third of its reasonable attorneys' fees and expert witness expenses. Deferred tax assets, net of valuation allowance Deferred Tax Assets, Net of Valuation Allowance Deferred tax assets, valuation allowance Deferred Tax Assets, Valuation Allowance Income tax benefit Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value Measurements, Recurring and Nonrecurring [Table] Measurement Frequency [Axis] Measurement Frequency [Axis] Fair Value, Measurement Frequency [Domain] Fair Value, Measurement Frequency [Domain] Recurring fair value measurements Fair Value, Measurements, Recurring [Member] Fair Value, Hierarchy [Axis] Fair Value, Hierarchy [Axis] Fair Value, Measurements, Fair Value Hierarchy [Domain] Fair Value, Measurements, Fair Value Hierarchy [Domain] Fair value inputs, Level 2 Fair Value, Inputs, Level 2 [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Non-current common stock warrants Net (loss) income for basic earnings per share Change in fair value of warrants Dilutive Securities, Effect on Basic Earnings Per Share Net (loss) income, adjusted for change in fair value of warrants for diluted earnings per share Net Income (Loss) Attributable to Parent, Diluted Weighted average shares Effect of potential common shares Incremental Common Shares Attributable to Call Options and Warrants Weighted-average shares: diluted (Loss) earnings per share: basic (Loss) earnings per share: diluted Recent Accounting Pronouncements [Abstract] Recent Accounting Pronouncements [Abstract] Recent Accounting Pronouncements Recent Accounting Pronouncements [Text Block] The entire disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items. Document and Entity Information [Abstract] Document and Entity Information [Abstract] Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Trading Symbol Trading Symbol Document Type Document Type Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Amendment Flag Amendment Flag Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Schedule of weighted-average assumptions utilized in the valuations Schedule of Share-based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions [Table Text Block] Tabular disclosure of the significant assumptions used during the year to estimate the fair value of equity instruments other than options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions. Balance Sheet Parenthetical [Abstract] Balance Sheet Parenthetical [Abstract] Common stock, par value Common Stock, Par or Stated Value Per Share Common stock, shares authorized Common Stock, Shares Authorized Common stock, shares issued Common Stock, Shares, Issued Common stock, shares outstanding Common Stock, Shares, Outstanding Schedule of accrued liabilities Schedule of Accrued Liabilities [Table Text Block]